IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

SemBioSys, Roslin Institute Make Proteins from GM Organisms

1:38 PM MDT | January 24, 2007 | Alex Scott

Biotechnology firm SemBioSys Genetics (Calgary, AB) says it has demonstrated that it can produce insulin for the treatment of diabetes by growing insulin in genetically modified (GM) safflower plants. The insulin is indistinguishable from human insulin, SemBioSys says. SemBioSys says its proprietary GM plant technology will revolutionize the economics associated with producing insulin. Eli Lilly, Novo Nordisk, and Sanofi-Aventis currently dominate the insulin market, which in 2005 was worth $7.2 billion. The company says its technology would reduce manufacturing...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa